Sugi Predict

Sugi Predict / Targets / JAK3

JAK3

Tyrosine-protein kinase JAK3 · P52333 · JAK3 on Sugi Atlas →

412,779 patent compounds predicted against JAK3, 238,156 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL20626 SCHEMBL20626 0.59 20/20
SCHEMBL30925 SCHEMBL30925 0.64 19/20
SCHEMBL21039 SCHEMBL21039 0.53 19/20
SCHEMBL30932 SCHEMBL30932 0.50 18/20
SCHEMBL19153 SCHEMBL19153 0.58 17/20
SCHEMBL19111 SCHEMBL19111 0.56 17/20
SCHEMBL20543 SCHEMBL20543 0.60 16/20
SCHEMBL30966 SCHEMBL30966 0.57 16/20
SCHEMBL20007 SCHEMBL20007 0.53 16/20
SCHEMBL99286 SCHEMBL99286 0.68 15/20
SCHEMBL100494 SCHEMBL100494 0.58 15/20
SCHEMBL24181 SCHEMBL24181 0.56 15/20
SCHEMBL21968 SCHEMBL21968 0.54 15/20
SCHEMBL24481 SCHEMBL24481 0.54 15/20
SCHEMBL25160 SCHEMBL25160 0.51 15/20
SCHEMBL100359 SCHEMBL100359 0.83 14/20
SCHEMBL100458 SCHEMBL100458 0.53 14/20
SCHEMBL99487 SCHEMBL99487 0.53 14/20
SCHEMBL98899 SCHEMBL98899 0.53 14/20
SCHEMBL100206 SCHEMBL100206 0.52 14/20

Clinical trials — most relevant to JAK3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis PHASE3UNKNOWN
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi. PHASE3COMPLETED
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis PHASE3ACTIVE_NOT_RECRUITING
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata PHASE3COMPLETED
A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis PHASE3ACTIVE_NOT_RECRUITING
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor PHASE2COMPLETED
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate PHASE2COMPLETED
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia PHASE2COMPLETED
Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata PHASE2COMPLETED
Baricitinib in CPPD - the BAPTIST Study PHASE2NOT_YET_RECRUITING
Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus PHASE1/PHASE2WITHDRAWN
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. PHASE2COMPLETED
An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia PHASE2UNKNOWN
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas PHASE2RECRUITING
A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia PHASE2UNKNOWN
Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19 PHASE2UNKNOWN
Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis PHASE2NOT_YET_RECRUITING
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients PHASE1RECRUITING
Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome PHASE1RECRUITING
Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions PHASE1COMPLETED
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea PHASE1COMPLETED
Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis PHASE1NOT_YET_RECRUITING
Ruxolitinib for Cancer Cachexia EARLY_PHASE1ACTIVE_NOT_RECRUITING
Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo nanUNKNOWN
Cutaneous JAK in Vitiligo and Acne Vulgaris. nanUNKNOWN
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease nanRECRUITING
Exploiting Leading Edge 7T MRI Brain Imaging to Decipher Olumiant's Mode of Analgesic Action in Rheumatoid Arthritis nanCOMPLETED
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts nanCOMPLETED
Evaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières Syndrome nanCOMPLETED
Immune Interactions in Severe Asthma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a JAK3 binder may also engage these)

ProteinNameSimilarity
Q63272 — 1.000 Q63272 →
TYK2 Non-receptor tyrosine-protein kinase TYK2 1.000 landscape →
Q62137 — 1.000 Q62137 →
Q9R117 — 1.000 Q9R117 →
D3ZEY4 — 0.996 D3ZEY4 →
P35546 — 0.995 P35546 →
Q9Y4C4 — 0.995 Q9Y4C4 →
Q6P5E8 — 0.994 Q6P5E8 →
Q00495 — 0.994 Q00495 →
O12990 — 0.994 O12990 →
CSF1R Macrophage colony-stimulating factor 1 receptor 0.993 landscape →
A2CI34 — 0.992 A2CI34 →
Q6XUX1 — 0.992 Q6XUX1 →
Q4VSN4 — 0.992 Q4VSN4 →
Q8VCC8 — 0.991 Q8VCC8 →
Q4TVR5 — 0.991 Q4TVR5 →
Q09178 — 0.991 Q09178 →
P13369 — 0.991 P13369 →
Q8TDY4 — 0.991 Q8TDY4 →
Q99ML2 — 0.991 Q99ML2 →
Q3V1N1 — 0.991 Q3V1N1 →
Q63474 — 0.991 Q63474 →
PTK2B Protein-tyrosine kinase 2-beta 0.990 landscape →
Q4VSN3 — 0.990 Q4VSN3 →
E9QAM5 — 0.990 E9QAM5 →
P0C0K6 — 0.990 P0C0K6 →
P70600 — 0.990 P70600 →
Q38SD2 — 0.990 Q38SD2 →
Q95KV0 — 0.990 Q95KV0 →
MATK Megakaryocyte-associated tyrosine-protein kinase 0.990 landscape →